News

Study May Reveal New Biomarkers Specific to SMA Types

New protein biomarkers that can distinguish between the different types of spinal muscular atrophy (SMA) were identified in a recent study. According to researchers, the discovery supports further investigation to determine their utility as biomarkers for patient classification, monitoring treatment effectiveness, and identifying severity-specific treatments. Findings were detailed in…

Endothelial Cell Defect Causes Microvasculopathy in SMA Mice

Microvasculopathy — damage to small blood vessels — occurs in patients with spinal muscular atrophy (SMA) and it can be made better by systemic SMN-restoring treatment, a new study reports. Survival motor neuron protein (SMN) is the protein that is defective in SMA. The available SMA treatments increase the…

Moderate Strength Training Benefits Man With SBMA

Moderate-intensity resistance training led to gains in muscle strength, balance and functional improvements in a man with mild impairments due to spinal and bulbar muscular atrophy (SBMA), according to a recent case report. “This case report highlights one individual with SBMA who benefitted from moderate-intensity exercise, including weight lifting,…

Respiratory Muscle Training May Help Breathing Function in SMA

Respiratory muscle training in spinal muscular atrophy (SMA) has the potential to stabilize or improve breathing function, a study has found, although the findings need to be substantiated by further research. In the study, adults and children with SMA demonstrated a dose-dependent increase in breathing muscle fatigue using a…

Double Take, SMA Runway Show, Features Styles With Accessibility

New York Fashion Week is known for its statement dresses and elegant models. But this year, one runway show will be slightly different, featuring people in wheelchairs wearing clothes designed for both fashion and accessibility. Models with spinal muscular atrophy (SMA) will drive down the runway on Sept. 8…

CADTH: Spinraza Should Not Be Funded for Adults in Canada

In its final decision, the Canadian Agency for Drugs and Technologies in Health (CADTH) recommended against Spinraza (nusinersen) being reimbursed to treat adults with spinal muscular atrophy (SMA).  The decision was met with dismay by the SMA community and Biogen, Spinraza’s manufacturer. “We are absolutely devastated for the…